GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

Research output: Contribution to journalArticlepeer-review

35 Citations (SciVal)

Abstract

Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.
Original languageEnglish
Pages (from-to)340-347
JournalCurrent Diabetes Reports
Volume7
Issue number5
Publication statusPublished - 2007

Subject classification (UKÄ)

  • Endocrinology and Diabetes

Fingerprint

Dive into the research topics of 'GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.'. Together they form a unique fingerprint.

Cite this